
ICON Public Limited Company ICLR
$ 107.45
0.59%
Annual report 2024
added 04-04-2026
ICON Public Limited Company General and Administrative Expenses 2011-2026 | ICLR
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses ICON Public Limited Company
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 585 M | - | 337 M | 326 M | 324 M | 326 M | 327 M | 336 M | 314 M | 281 M | 256 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 585 M | 256 M | 341 M |
Quarterly General and Administrative Expenses ICON Public Limited Company
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 195 M | - | 207 M | 110 M | 86 M | - | 82.7 M | 83.5 M | 87.2 M | - | 85.4 M | 83.2 M | 81.9 M | - | 80.8 M | 80.9 M | 80.9 M | - | 79.4 M | 80.8 M | 81.4 M | - | 81.2 M | 80.2 M | 80.8 M | - | 82.4 M | 81.3 M | 79.6 M | - | 84.5 M | 87.6 M | 78.9 M | - | 81.4 M | 77.5 M | 75.6 M | - | 70.7 M | 69.4 M | 67.5 M | - | 71.6 M | 57.3 M | 59.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 207 M | 57.3 M | 86.9 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
BioNano Genomics
BNGO
|
35.2 M | $ 1.14 | 0.44 % | $ 6.21 M | ||
|
Burning Rock Biotech Limited
BNR
|
490 M | $ 16.07 | 1.39 % | $ 173 M | ||
|
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
1.62 B | $ 115.09 | 0.03 % | $ 35 B | ||
|
Interpace Biosciences
IDXG
|
9.48 M | $ 2.25 | -2.17 % | $ 9.95 M | ||
|
Aspira Women's Health
AWH
|
7.96 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
9.46 M | - | - | $ 9.42 M | ||
|
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | ||
|
CareDx, Inc
CDNA
|
108 M | $ 16.32 | 1.65 % | $ 870 M | ||
|
Medpace Holdings
MEDP
|
198 M | $ 498.22 | 0.95 % | $ 14.4 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M | ||
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M | ||
|
Myriad Genetics
MYGN
|
257 M | $ 4.45 | 2.3 % | $ 412 M | ||
|
NeoGenomics
NEO
|
273 M | $ 7.87 | 2.34 % | $ 1.01 B | ||
|
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | ||
|
Co-Diagnostics
CODX
|
9.06 M | $ 1.4 | 2.19 % | $ 1.86 M | ||
|
Exact Sciences Corporation
EXAS
|
889 M | - | - | $ 19.8 B | ||
|
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | ||
|
Castle Biosciences
CSTL
|
200 M | $ 23.05 | -0.35 % | $ 640 M | ||
|
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | ||
|
Senseonics Holdings
SENS
|
52.5 M | $ 6.62 | -0.9 % | $ 276 M | ||
|
Charles River Laboratories International
CRL
|
743 M | $ 176.51 | 0.49 % | $ 8.75 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | ||
|
Soleno Therapeutics
SLNO
|
132 M | $ 52.58 | -0.1 % | $ 2.67 B | ||
|
Danaher Corporation
DHR
|
8.24 B | $ 190.99 | 0.73 % | $ 136 B | ||
|
Neuronetics
STIM
|
31.5 M | $ 1.37 | 1.11 % | $ 90.4 M | ||
|
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
1.09 B | $ 122.69 | 1.46 % | $ 19.5 B | ||
|
Fulgent Genetics
FLGT
|
88.1 M | $ 14.96 | 3.67 % | $ 452 M | ||
|
Thermo Fisher Scientific
TMO
|
8.73 B | $ 500.25 | 0.83 % | $ 189 B | ||
|
Trinity Biotech plc
TRIB
|
24.7 M | $ 0.69 | -3.28 % | $ 61.9 M | ||
|
Guardant Health
GH
|
211 M | $ 79.27 | 0.85 % | $ 9.94 B | ||
|
QIAGEN N.V.
QGEN
|
128 M | - | - | $ 10.6 B | ||
|
Twist Bioscience Corporation
TWST
|
247 M | $ 48.44 | 1.11 % | $ 2.9 B | ||
|
Anixa Biosciences
ANIX
|
6.63 M | $ 2.73 | 1.49 % | $ 88.6 K | ||
|
Biomerica
BMRA
|
2.98 M | $ 2.1 | -2.1 % | $ 4.82 M | ||
|
Invitae Corporation
NVTA
|
192 M | - | - | $ 21.2 M | ||
|
Koninklijke Philips N.V.
PHG
|
599 M | $ 28.26 | -0.18 % | $ 20 B | ||
|
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 261.12 | 0.07 % | $ 21.7 B | ||
|
Natera
NTRA
|
589 M | $ 197.55 | 2.34 % | $ 19.4 B | ||
|
Celcuity
CELC
|
27.2 M | $ 118.08 | 0.8 % | $ 5.52 B | ||
|
Lantheus Holdings
LNTH
|
275 M | $ 80.41 | -0.23 % | $ 5.43 B | ||
|
Waters Corporation
WAT
|
240 M | $ 318.26 | -0.54 % | $ 19 B |